NASDAQ:JAZZ Jazz Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $153.49 +2.72 (+1.80%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$150.47▼$153.9350-Day Range$141.59▼$168.0052-Week Range$117.64▼$186.22Volume409,016 shsAverage Volume597,741 shsMarket Capitalization$9.58 billionP/E RatioN/ADividend YieldN/APrice Target$204.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock Forecast (MarketRank)Overall MarketRank™2.43 out of 5 starsMedical Sector174th out of 1,418 stocksPharmaceutical Preparations Industry68th out of 679 stocksAnalyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $204.14, Jazz Pharmaceuticals has a forecasted upside of 33.1% from its current price of $153.38.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesJazz Pharmaceuticals has received 1,036 “outperform” votes. (Add your “outperform” vote.)Underperform VotesJazz Pharmaceuticals has received 249 “underperform” votes. (Add your “underperform” vote.)Community SentimentJazz Pharmaceuticals has received 80.62% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote “Outperform” if you believe JAZZ will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,096,461.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions93.23% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 8.15% in the coming year, from $14.73 to $15.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -20.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -20.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Jazz Pharmaceuticals (NASDAQ:JAZZ)Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock News HeadlinesJune 23, 2022 | finance.yahoo.comAre Options Traders Betting on a Big Move in Jazz Pharmaceuticals (JAZZ) Stock?June 16, 2022 | seekingalpha.comAvadel: Further Delay, But Some Light At The End Of The TunnelJune 15, 2022 | seekingalpha.comJazz to start clinical trial for tumor candidate after FDA nodJune 15, 2022 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $208.14 Consensus PT from BrokeragesJune 15, 2022 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Average Rating of "Buy" from AnalystsJune 14, 2022 | seekingalpha.comJazz initiated Buy at UBS on underappreciated potential of cannabidiol drugJune 14, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Jazz PharmaceuticalsJune 14, 2022 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Receives New Coverage from Analysts at UBS GroupJune 12, 2022 | americanbankingnews.comSamantha Pearce Sells 8,487 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockJune 9, 2022 | americanbankingnews.comResearch Analysts Offer Predictions for Jazz Pharmaceuticals plc's FY2023 Earnings (NASDAQ:JAZZ)June 8, 2022 | au.finance.yahoo.comThe Post Traumatic Stress Disorder (PTSD) Market To Surge with a CAGR of 8.3% in the 7MM During the Study Period (2019-32) | DelveInsightJune 7, 2022 | finance.yahoo.comJazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual MeetingJune 5, 2022 | americanbankingnews.comBruce C. Cozadd Sells 6,362 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees3,200Year Founded2003Company Calendar Last Earnings5/04/2022Today6/24/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$204.14 High Stock Price Forecast$225.00 Low Stock Price Forecast$174.00 Forecasted Upside/Downside+33.0%Consensus RatingModerate Buy Rating Score (0-4)2.81818181818182 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($7.510010) Trailing P/E RatioN/A Forward P/E Ratio10.42 P/E Growth1.24Net Income$-329.67 million Net Margins-13.63% Pretax Margin-7.34% Return on Equity22.45% Return on Assets7.06% Debt Debt-to-Equity Ratio1.66 Current Ratio3.39 Quick Ratio2.06 Sales & Book Value Annual Sales$3.09 billion Price / Sales3.10 Cash Flow$23.65 per share Price / Cash Flow6.49 Book Value$64.51 per share Price / Book2.38Miscellaneous Outstanding Shares62,443,000Free Float59,696,000Market Cap$9.58 billion OptionableOptionable Beta0.80 Social Links Jazz Pharmaceuticals Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Jazz Pharmaceuticals stock. View analyst ratings for Jazz Pharmaceuticals or view top-rated stocks. What is Jazz Pharmaceuticals' stock price forecast for 2022? 11 Wall Street analysts have issued 12 month target prices for Jazz Pharmaceuticals' shares. Their JAZZ stock forecasts range from $174.00 to $225.00. On average, they anticipate Jazz Pharmaceuticals' share price to reach $204.14 in the next year. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for Jazz Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Jazz Pharmaceuticals' stock performed in 2022? Jazz Pharmaceuticals' stock was trading at $127.40 on January 1st, 2022. Since then, JAZZ stock has increased by 20.5% and is now trading at $153.49. View the best growth stocks for 2022 here. When is Jazz Pharmaceuticals' next earnings date? Jazz Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Jazz Pharmaceuticals. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings results on Wednesday, May, 4th. The specialty pharmaceutical company reported $3.13 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.13. The specialty pharmaceutical company had revenue of $813.72 million for the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a positive trailing twelve-month return on equity of 22.45% and a negative net margin of 13.63%. The business's revenue for the quarter was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business earned $3.42 EPS. View Jazz Pharmaceuticals' earnings history. What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.70 billion, compared to the consensus revenue estimate of $3.58 billion. Who are Jazz Pharmaceuticals' key executives? Jazz Pharmaceuticals' management team includes the following people: Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO (Age 58, Pay $2.27M) (LinkedIn Profile)Mr. Daniel N. Swisher Jr., Pres (Age 59, Pay $1.27M)Ms. Renee D. Gala, Exec. VP & CFO (Age 50, Pay $1.03M)Mr. Christopher John Tovey BSc, Exec. VP, COO and MD of Europe & International (Age 57, Pay $880.61k)Dr. Robert Iannone M.D., Exec. VP and Global Head of R&D (Age 55, Pay $983.25k)Ms. Patricia Carr, Sr. VP & Chief Accounting Officer (Age 51) (LinkedIn Profile)Dr. Finbar Larkin Ph.D., Sr. VP of Technical Operations (Age 64)Ms. Andrea N. Flynn Ph.D., VP & Head of Investor RelationsMs. Neena M. Patil J.D., Chief Legal Officer and Sr. VP of Legal & Corp. Affairs (Age 47) (LinkedIn Profile)Dr. George Christopher Eliades Ph.D., Sr. VP of Corp. Devel. & Chief Transformation Officer (Age 52) What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals CEO Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among Jazz Pharmaceuticals' employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Jazz Pharmaceuticals' key competitors? Some companies that are related to Jazz Pharmaceuticals include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER). View all of JAZZ's competitors. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). What is Jazz Pharmaceuticals' stock symbol? Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ." Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.36%), Vanguard Group Inc. (8.99%), JPMorgan Chase & Co. (5.28%), Wellington Management Group LLP (4.21%), State Street Corp (3.76%) and LSV Asset Management (2.90%). Company insiders that own Jazz Pharmaceuticals stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Catherine A Sohn, Elmar Schnee, Finbar Larkin, James E Flynn, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Paul Treacy, Samantha Pearce and Seamus Mulligan. View institutional ownership trends for Jazz Pharmaceuticals. Which institutional investors are selling Jazz Pharmaceuticals stock? JAZZ stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Polar Capital Holdings Plc, Goldman Sachs Group Inc., Renaissance Technologies LLC, Victory Capital Management Inc., Assenagon Asset Management S.A., Bellevue Group AG, and Rhenman & Partners Asset Management AB. Company insiders that have sold Jazz Pharmaceuticals company stock in the last two years include Anne Oriordan, Bruce C Cozadd, Elmar Schnee, Finbar Larkin, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, and Samantha Pearce. View insider buying and selling activity for Jazz Pharmaceuticals or view top insider-selling stocks. Which institutional investors are buying Jazz Pharmaceuticals stock? JAZZ stock was bought by a variety of institutional investors in the last quarter, including Atika Capital Management LLC, Wellington Management Group LLP, Sumitomo Mitsui Trust Holdings Inc., Woodline Partners LP, Great Point Partners LLC, Loomis Sayles & Co. L P, JPMorgan Chase & Co., and Braun Stacey Associates Inc.. View insider buying and selling activity for Jazz Pharmaceuticals or or view top insider-buying stocks. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Jazz Pharmaceuticals' stock price today? One share of JAZZ stock can currently be purchased for approximately $153.49. How much money does Jazz Pharmaceuticals make? Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.58 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329.67 million in net income (profit) each year or ($7.510010) on an earnings per share basis. How many employees does Jazz Pharmaceuticals have? Jazz Pharmaceuticals employs 3,200 workers across the globe. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More When was Jazz Pharmaceuticals founded? Jazz Pharmaceuticals was founded in 2003. How can I contact Jazz Pharmaceuticals? Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for Jazz Pharmaceuticals is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at [email protected], or via fax at 353-1634-7850. This page (NASDAQ:JAZZ) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here